Health Care · Surgical & Medical Instruments & Apparatus

HAE HAEMONETICS CORP SEC Filings & Insider Trading Activity 2026

company
CIK 31314397 filings
Russell 2000

HAE at a glance

HAEMONETICS CORP (HAE, SEC CIK 313143) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended March 28, 2026 (FY2026), HAEMONETICS CORP (HAE) reported revenue of $1.3 billion (down 2.0% from FY2025) and net income of $97.3 million. Diluted EPS was $2.05.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding HAEMONETICS CORP (HAE) shares worth $2.5 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Maunsell Farris Maryanne on November 11, 2026 of 836 shares at $120.99 per share.
  • In the last 90 days, HAE insiders reported 0 open-market purchases ($0) and 1 open-market sale ($101K) on Form 4, a net sale of $101K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$1.3B
−2.0% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$101K
13F holders
34 funds
$2.5B · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 26, 2026

Risk Factors

  • No material changes from the fiscal 2026 Form 10-K risk factors
  • Carried-forward risks remain unchanged, with no new triggers identified

Management Discussion & Analysis

  • Revenue $357.8M, up 9.3% YoY from $327.3M
  • Operating margin 21.0% vs 17.9% YoY, net margin 12.9% vs 11.8%
  • Best performer: Plasma revenue $162.6M, up 16.5%; worst: Interventional Technologies $60.5M, up 2.4%
  • Cash $260.7M vs $245.4M; operating cash flow $180.4M vs $128.7M for six months
  • $100.0M revolving-credit repayment; CSL rollout expected by end of calendar year 2027, timing subject to change

AI summary of the HAE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Haemonetics announced fiscal 2027 second-quarter and first-half financial results
  • Results cover the quarter ended September 26, 2026

Item EX-99.1: Item EX-99.1

  • Q2 FY27 revenue $357.8M, up 9.3%, with organic growth 10.0%, signaling broad operating momentum
  • Apheresis led growth at 12.6% reported and 13.6% organic, while MedSurg delivered 5.1% reported growth
Filed Oct 8, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • CSL expects rollout of Haemonetics’ NexSys PCS devices and Persona PLUS disposables across all current U.S. plasma centers by end-2027
  • Potentially broad customer conversion expands Haemonetics’ recurring disposable-product opportunity with a major plasma collector
Filed Aug 18, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Supply agreement with CSL Plasma for NexSys PCS devices, Persona PLUS technology and related U.S. disposables
  • Non-exclusive arrangement with no minimum purchase commitments, limiting near-term revenue certainty

AI summaries of HAE 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HAE

Don't miss the next HAE filing

  • Alerts as it files. A push when HAE files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HAE, by share count.
  • Ask anything. An AI agent that reads every HAE filing and answers with sources.

HAE alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Maunsell Farris MaryanneMNov 11, 2026-
Maunsell Farris MaryanneFNov 11, 2026$121.10
Maunsell Farris MaryanneMNov 11, 2026$70.31
Maunsell Farris MaryanneSellNov 11, 2026$120.99
Maunsell Farris MaryanneMNov 11, 2026-
Maunsell Farris MaryanneMNov 11, 2026-
Maunsell Farris MaryanneMNov 11, 2026$89.16
Maunsell Farris MaryanneMNov 11, 2026$95.73

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$1.4B$1.3B
Gross Profit-$749.0M$787.6M
Operating Income-$221.8M$156.7M
Net Income-$167.7M$97.3M
Gross Margin-55.0%59.0%
Op. Margin-16.3%11.7%
Net Margin-12.3%7.3%
Balance Sheet
Total Assets$2.2B$2.5B$2.4B
Equity-$820.8M$796.3M
ROE-20.4%12.2%
Per Share
EPS-$3.31$2.05
Cash Flow
Operating CF-$181.7M$293.2M
CapEx$66.3M$39.3M$32.8M

Source: XBRL data in HAEMONETICS CORP (HAE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HAE share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HAE shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$2.51B
Q2 202635$1.79B
Q1 202636$1.31B
Q4 202529$1.99B
Q3 202529$1.14B
Q2 202529$1.57B
Q1 202526$877.8M
Q4 202423$925.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HAE filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 3, 2026--
8-KOct 8, 2026Analysis-
8-KAug 18, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 28, 2026--
8-KJul 28, 2026Analysis-
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 5, 2026Analysis
10-KMay 20, 2026-
4May 19, 2026-
4May 19, 2026-
8-KMay 7, 2026Analysis
4May 5, 2026--

Related Health Care companies

All Health Care →

HAE SEC filings: frequently asked questions

Are HAE insiders buying or selling?

In the last 90 days, HAEMONETICS CORP (HAE) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $101,148 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold HAE stock?

As of September 30, 2026, the largest HAEMONETICS CORP (HAE) holders among the 13F filers tracked by SignalX were BlackRock ($626.9 million), Vanguard Portfolio Management LLC ($263.4 million), Vanguard Capital Management LLC ($215.4 million), AQR Capital Management ($189.5 million), State Street Corp ($189.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HAE's revenue in fiscal year 2026?

For the fiscal year ended March 28, 2026 (FY2026), HAEMONETICS CORP (HAE) reported revenue of $1.3 billion (down 2.0% from FY2025) and net income of $97.3 million. Diluted EPS was $2.05. The figures come from the XBRL data in the 10-K.

What did HAE report in its latest 8-K?

HAEMONETICS CORP (HAE) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Haemonetics announced fiscal 2027 second-quarter and first-half financial results.

What are the latest HAE SEC filings?

HAEMONETICS CORP (HAE) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is HAE's SEC CIK number?

HAEMONETICS CORP (HAE)'s SEC Central Index Key (CIK) is 313143. EDGAR lists every HAE filing under that number.

Ask anything about HAE

The research agent reads HAE's filings, financials, insider trades and 13F holders, then answers with sources.